CLINICAL_TRIALS ClinicalTrials.gov record update

A Single-Arm, Stratified Two-Stage Phase II Study of Low-Dose Apatinib Plus Physician's Choice Monotherapy Chemotherapy (TPC) in Patients With HER2-Positive and HER2-Low Advanced Breast Cancer After Progression on Antibody-Drug Conjugate Therapy

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT07907354
Title field or adapter rule: {'original_value': "A Single-Arm, Stratified Two-Stage Phase II Study of Low-Dose Apatinib Plus Physician's Choice Monotherapy Chemotherapy (TPC) in Patients With HER2-Positive and HER2-Low Advanced Breast Cancer After Progression on Antibody-Drug Conjugate Therapy", 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At: 2026-10-31T23:27:27.204534+00:00
Published At: 2026-10-30T00:00:00+00:00
Record Updated At: 2026-10-30
Source Retrieved At: 2026-10-31T22:19:00.066997+00:00
Timestamp Basis: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

protocolSection.conditionsModule.conditions: ["Breast Neoplasms", "Advanced Breast Cancer", "HER2-positive Breast Cancer", "HER2-low Breast Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct: {"date": "2026-10-30", "type": "ACTUAL"}
protocolSection.identificationModule.nctId: "NCT07907354"
protocolSection.identificationModule.officialTitle: "A Single-Arm, Stratified Two-Stage Phase II Study of Low-Dose Apatinib Plus Physician\u0027s Choice Monotherapy Chemotherapy (TPC) in Patients With HER2-Positive and HER2-Low Advanced Breast Cancer After Progression on Antibody-Drug Conjugate Therapy"
protocolSection.statusModule.overallStatus: "NOT_YET_RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct: null

{'armGroupLabels': ["Apatinib + Physician's Choice Chemotherapy"], 'description': 'Apatinib mesylate tablets, 250 mg, orally, once daily (QD). Dose modifications (interruption, reduction to 250 mg every other day or 3 days on/4 days off) are allowed per protocol for the management of adverse events (e.g., hypertension, proteinuria, hand-foot syndrome, diarrhea).', 'name': 'Apatinib mesylate', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ["Apatinib + Physician's Choice Chemotherapy"], 'description': "Single-agent chemotherapy selected by the investigator from a pre-specified list, based on patient's prior treatment history (e.g., prior progression on 8201a or A1811), performance status, and investigator judgment. Oral or intravenous administration is allowed.\n\nPermitted agents and their cycles:\n\n* Capecitabine: 1000-1250 mg/m² PO BID, days 1-14, repeat every 21 days\n* Vinorelbine: 25 mg/m² IV, days 1/8/15, repeat every 28 days\n* Paclitaxel: 80 mg/m² IV, days 1/8/15, repeat every 28 days (or 175 mg/m² IV day 1, repeat every 21 days per investigator choice)", 'name': "Physician's choice chemotherapy", 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.